Utama › Poliradikuloneuropati Demielinasi Inflamatori Kronik › Pennsylvania
Kajian klinikal Poliradikuloneuropati Demielinasi Inflamatori Kronik di Pennsylvania
6 kajian untuk Poliradikuloneuropati Demielinasi Inflamatori Kronik sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Site Number - 1616, Philadelphia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07032662A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- Penn Medicine University City, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07091630A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- Perelman Center for Advanced Medicine, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06920004A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Penn State Health Milton South Hershey Medical Center- Site Number : 8400042, Hershey
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06290141Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
- Investigational Site, Swiftwater
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06968975A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Penn Blood Disorders Program - Hospital of The University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Apr 2026 · NCT06798012Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.